A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2017

At a glance

  • Drugs Bavituximab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2013 Final results were presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Peregrine Pharmaceuticals media release.
    • 20 May 2013 Final results will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Peregrine media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top